TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3484505

Group type: EXPERIMENTAL
Intervention: Vaccine intervention (specifics not provided)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 287
Study: 29446209

Group type: EXPERIMENTAL
Intervention: iChoose Kidney decision aid
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard transplantation education (control)
Number of subjects: 443
Study: 27014935

Group type: COMPARATOR
Intervention: PFMT with EMG biofeedback and sham NMES
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PFMT with EMG biofeedback and intravaginal NMES
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PFMT with EMG biofeedback and TTNS
Number of subjects: 30
Study: 24528987

Group type: EXPERIMENTAL
Intervention: Thoracoscopic clipping (TC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transcatheter occlusion (TO)
Number of subjects: 100
Study: 24601188

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dry care
Number of subjects: 300

Group type: COMPARATOR
Intervention: All groups (Ethanol, Human milk, Dry care)
Number of subjects: 300
Study: 20862711

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 34
Study: 17341882

Group type: EXPERIMENTAL
Intervention: Mistletoe infusion (Iscador)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 62
Study: 15487766

Group type: EXPERIMENTAL
Intervention: 1600 microg/day of selenized yeast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3200 microg/day of selenized yeast
Number of subjects: 24
Study: 11903959

Group type: EXPERIMENTAL
Intervention: SOD1 activity in patients with Down's syndrome
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin and copper levels in patients with Down's syndrome
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin activities in patients with Down's syndrome
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SOD1 activity in patients aged 40 years or older
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Specific oxidative activity in patients aged 40 years or older
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin oxidative activity in patients aged 40 years or older
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ceruloplasmin and copper levels in controls
Number of subjects: 35

Group type: COMPARATOR
Intervention: SOD1 activity in controls
Number of subjects: 35
Study: 9815869

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7886867

Group type: EXPERIMENTAL
Intervention: Noncontact transscleral Nd: YAG cyclophotocoagulation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Repeated procedures
Number of subjects: 500
Study: 3220614

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg or 75 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31820121

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg) with cholecalciferol (5600 IU)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Risedronate (35 mg) alone
Number of subjects: 841
Study: 30365821

Group type: EXPERIMENTAL
Intervention: 4 x 2 min at 30% of the maximal voluntary contraction (S30%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 x 2 min at 50% of the maximal voluntary contraction (S50%2min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 x 3 min at 30% of the maximal voluntary contraction (S30%3min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 12
Study: 26930498

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24280999

Group type: EXPERIMENTAL
Intervention: NUCAI (nurse counselling and after intervention)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: NUCAI
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study: 22155532

Group type: EXPERIMENTAL
Intervention: Ex+Ca+ (exercise with calcium supplementation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ex+Ca- (exercise without calcium supplementation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ex-Ca+ (non-exercise with calcium supplementation)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ex-Ca- (non-exercise without calcium supplementation)
Number of subjects: 54
Study: 20712737

Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in children aged 10 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion in autism
Number of subjects: 0
Study: 17550040

Group type: EXPERIMENTAL
Intervention: Topically applied vitamin 'E' (100 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Systemically administered vitamin 'E'
Number of subjects: 80
Study: 15970639

Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic saline (3 times daily for 7 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic saline
Number of subjects: 44

Group type: COMPARATOR
Intervention: No nasal irrigation (control)
Number of subjects: 44
Study: 12453080

Group type: EXPERIMENTAL
Intervention: Physiotherapy and treadmill training (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treadmill training only (group B)
Number of subjects: 28
Study: 10073976

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use with factor II:A20210
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use with factor V:A1691
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Factor II:A20210
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Factor V:A1691
Number of subjects: 148

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 148
Study: 7866978

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8
Study: 1959365

Group type: EXPERIMENTAL
Intervention: Epidural morphine (7 mg in 14 mL of sterile saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline 14 mL)
Number of subjects: 20
Study: 7176840

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 484
Study: 29741284

Group type: COMPARATOR
Intervention: Placebo arm of the 3‐year Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA)
Number of subjects: 559
Study: 28378356

Group type: EXPERIMENTAL
Intervention: Processed Nigella sativa seed powder (2 g/day in divided doses)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25661189

Group type: EXPERIMENTAL
Intervention: PAL1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAL2
Number of subjects: 0

Group type: COMPARATOR
Intervention: REF
Number of subjects: 0
Study: 23842758

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: QUADROX-i oxygenator with external arterial filter under PP
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CAPIOX-FX25 and SYNTHESIS oxygenators
Number of subjects: 78
Study: 20605696

Group type: EXPERIMENTAL
Intervention: Green tea beverage (4 cups/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No treatment (4 cups water/d)
Number of subjects: 35
Study: 19563059

Group type: EXPERIMENTAL
Intervention: Group C (three coagulation points per ovary)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group D (four to five coagulation points per ovary)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group A (one coagulation point per ovary)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group B (two coagulation points per ovary)
Number of subjects: 56
Study: 17692724

Group type: EXPERIMENTAL
Intervention: Garenoxacin (oral or intravenous) 50-1200 mg/d for 1 to 28 days
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 15453552

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control oral appliance
Number of subjects: 61
Study: 11816915

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 600
Study: 9802141

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg o.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7543352

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rhGM‐CSF, 250 micrograms/m2/day (trial 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhGM‐CSF, 250 micrograms/m2/day (trial 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 70
Study: 2083956

Group type: EXPERIMENTAL
Intervention: Nebuhaler (conical spacer with inhalation valve)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tube spacer
Number of subjects: 20
Study: 463953

Group type: EXPERIMENTAL
Intervention: Ovulation Method (OM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptothermal Method (STM)
Number of subjects: 0
Study: 31056465

Group type: EXPERIMENTAL
Intervention: 20-minute postpartum rounding video based on 4C-ID principles
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 78
Study: 28429365

Group type: EXPERIMENTAL
Intervention: Screwed implant-abutment connection (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cemented implant-abutment connection (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinical parameters (PPD > 3 mm and m SBI > 0) in Group 1
Number of subjects: 20
Study: 26027630

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg Q2W at week 12 if LDL-C ≥70 mg/dL)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo (Q2W)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316

Group type: COMPARATOR
Intervention: Alirocumab and Placebo
Number of subjects: 316
Study: 23529851

Group type: EXPERIMENTAL
Intervention: Group HDO (haloperidol 2 mg, dexamethasone 8 mg, ondansetron)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group O (ondansetron 8 mg)
Number of subjects: 90
Study: 20572860

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 250) received multiple measures for caries control.
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (n = 247) received standard dental care.
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Both groups received standard dental care during the post-trial period (2005-2008).
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 250)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (n = 247)
Number of subjects: 497
Study: 18795629

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg, once daily) after ESWL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no tamsulosin)
Number of subjects: 80
Study: 16901180

Group type: EXPERIMENTAL
Intervention: Single-day famciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12929897

Group type: EXPERIMENTAL
Intervention: CATCH program (FI schools)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Former control schools (FC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Unexposed control schools (UC)
Number of subjects: 96
Study: 10779188

Group type: EXPERIMENTAL
Intervention: Capsaicin (3 x 10(‐6) mol. dissolved in 70% ethanol)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Capsaicin vehicle (70% ethanol)
Number of subjects: 51
Study: 8630960

Group type: EXPERIMENTAL
Intervention: Chamomile mouthwash, administered thrice daily for 14 days.
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo mouthwash, administered thrice daily for 14 days.
Number of subjects: 164
Study: 10149894

Group type: EXPERIMENTAL
Intervention: Hercules injections
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional manual injections
Number of subjects: 200
Study: 6086181

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 5
Study: 31436395

Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (INO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC; intensive chemotherapy)
Number of subjects: 0
Study: 30304715

Group type: EXPERIMENTAL
Intervention: High miR‐125b level group (n = 77)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Low miR‐125b level group (n = 77)
Number of subjects: 154
Study: 27553751

Group type: EXPERIMENTAL
Intervention: Subcutaneous mepolizumab treatment
Number of subjects: 558
Study: 25259640

Group type: EXPERIMENTAL
Intervention: Cardiometabolic health nurse intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23082124

Group type: EXPERIMENTAL
Intervention: High-performance water filter and jerry cans for safe storage
Number of subjects: 120
Study: 20929607

Group type: EXPERIMENTAL
Intervention: C1‐INH replacement products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma kallikrein inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bradykinin B₂‐receptor antagonist
Number of subjects: 0
Study: 18064330

Group type: EXPERIMENTAL
Intervention: Clopidogrel (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin
Number of subjects: 31
Study: 18232183

Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg three times daily for 12 weeks
Number of subjects: 129
Study: 14763916

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 3 weeks (2.55 MJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Starvation for 6 days
Number of subjects: 12
Study: 10437189

Group type: EXPERIMENTAL
Intervention: Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Scutellariae, Radix et Rhizoma Rhei Preparata
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8473583

Group type: EXPERIMENTAL
Intervention: Culturally tailored videotape presented by African-American women
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard public health service tape on AIDS prevention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ethnically matched public health service tape
Number of subjects: 106
Study: 3700932

Group type: EXPERIMENTAL
Intervention: Doxepin (10 to 20 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30801507

Group type: EXPERIMENTAL
Intervention: Microblepharon exfoliation
Number of subjects: 30

Group type: COMPARATOR
Intervention: LidHygenix (hypoallergenic foam cleanser)
Number of subjects: 30
Study: 28017406

Group type: EXPERIMENTAL
Intervention: Bortezomib with lenalidomide and dexamethasone (VRd)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 525
Study: 25393894

Group type: EXPERIMENTAL
Intervention: Y-60H IOL
Number of subjects: 65

Group type: COMPARATOR
Intervention: Micro AY IOL
Number of subjects: 65
Study: 25164259

Group type: EXPERIMENTAL
Intervention: Group-based dietary intervention (individualized calorie goals, weight maintenance advice, Dietary Approaches to Stop Hypertension dietary pattern, weekly group meetings)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Group-based dietary intervention
Number of subjects: 114
Study: 23866514

Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg daily dose)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rivastigmine (4.5 mg daily dose)
Number of subjects: 56
Study: 18785988

Group type: EXPERIMENTAL
Intervention: LAB4 multistrain probiotic preparation (2.5 × 10(10) cfu/capsule)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17468062

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Oral alendronate (ALN) 70 mg
Number of subjects: 225
Study: 15131770

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nondiabetic children (control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic females
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic males
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with poor glycemic control (HbA(1C) > 9.0%)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with raised total cholesterol (TC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with raised triglycerides (TG)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with family history of cardiovascular disease (CVD)
Number of subjects: 150
Study: 11395209

Group type: EXPERIMENTAL
Intervention: Granzyme B levels in peripheral blood mononuclear cells stimulated with live influenza virus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cytokine levels in peripheral blood mononuclear cells stimulated with live influenza virus
Number of subjects: 100
Study: 9741525

Group type: EXPERIMENTAL
Intervention: Veno-venous ultrafiltration (UF) immediately after CPB (Group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Veno-venous ultrafiltration (UF) 10 min after CPB (Group B)
Number of subjects: 23
Study: 8116042

Group type: EXPERIMENTAL
Intervention: Adjunct treatment with 10 courses of photochemotherapy (PCT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adjunct treatment with 20 courses of photochemotherapy (PCT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group with no additional treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both PCT schedules (10 and 20 courses)
Number of subjects: 15
Study: 3136642

Group type: EXPERIMENTAL
Intervention: High lysine (206 mg.kg‐1.d‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low lysine (158 mg.kg‐1.d‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High threonine (147 mg.kg‐1.d‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low threonine (113 mg.kg‐1.d‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High histidine (124 mg.kg‐1.d‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low histidine (85 mg.kg‐1.d‐1)
Number of subjects: 23
Study: 31361922

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg annually
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) switching
Number of subjects: 43
Study: 28583098

Group type: EXPERIMENTAL
Intervention: Increase in Relational Capacity by one standard deviation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Identity Integration
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-control
Number of subjects: 113
Study: 25644342

Group type: EXPERIMENTAL
Intervention: Cereal-based bread
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 30
Study: 23866736

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ Winthrop®)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL, Coartem®)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Both ASAQ and AL
Number of subjects: 1300
Study: 21788827

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy on tissue expanders (group 2)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy on permanent implants (group 1)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Nonirradiated control group
Number of subjects: 257
Study: 19830868

Group type: EXPERIMENTAL
Intervention: Alcon CZ70BD PMMA suspensory IOL (Group I)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Akreos Adapt four-haptic hydrophilic acrylic foldable IOL (Group II)
Number of subjects: 23
Study: 18038919

Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg at weeks 0 and 2, open-label infliximab 5mg/kg at weeks 6 and 14
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo at weeks 0 and 2, open-label infliximab 5mg/kg at weeks 6 and 14
Number of subjects: 19
Study: 15356432

Group type: EXPERIMENTAL
Intervention: Bretylium
Number of subjects: 0
Study: 14627176

Group type: EXPERIMENTAL
Intervention: losartan/HCTZ (50 mg/12.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: losartan (50 mg)
Number of subjects: 0
Study: 11128853

Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in lower leg muscles increased from 24.6 +/- 9.5% to 43.1 +/- 4.7%; P < 0.05
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in heart increased from 2.3 +/- 0.4% to 2.8 +/- 0.6%; P < 0.05
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting for 35 min after FDG injection; FDG uptake in abdominal region reduced from 37.3 +/- 7.2% to 19.7 +/- 4.9%; P < 0.05
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in brain remained stable at 11.9 +/- 2.8% at rest and 10.3 +/- 2.5% after exercise; P not specified
Number of subjects: 12
Study: 9175961

Group type: EXPERIMENTAL
Intervention: Combined spinal-extradural technique with 2.25 ml of 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study: 1398497

Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 131
Study: 3083995

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg prednisolone daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg prednisolone daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg prednisolone daily
Number of subjects: 10
Study: 31678411

Group type: EXPERIMENTAL
Intervention: Nutritional prehabilitation
Number of subjects: 0